|Bid||0.4606 x 1000|
|Ask||0.4720 x 3000|
|Day's Range||0.4527 - 0.4807|
|52 Week Range||0.4500 - 3.5500|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 23, 2022 - May 27, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.30|
Subscribe to Yahoo Finance Plus to view Fair Value for MEIP
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 23, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2022, and highlighted recent corporate events.
SAN DIEGO, May 17, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022. The company will present a company overview and business update available for on-demand listening starting Tuesday, May 24, 2022, 7:00 a.m. Eastern Time that will be archived for 90 days.